Progyny, Inc. Cost of Revenue
Progyny, Inc. (PGNY) reported Cost of Revenue of $261.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-07
- Progyny, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $261.21M, a 2.88% increase year-over-year.
- Progyny, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $245.43M, a 1.13% decline year-over-year.
- Progyny, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $241.52M, a 2.78% increase year-over-year.
- Progyny, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $240.51M, a 5.77% increase year-over-year.
- Progyny, Inc. cost of goods and services sold for fiscal 2025 was $984.18M, a 7.69% increase from fiscal 2024.
- Progyny, Inc. cost of goods and services sold for fiscal 2024 was $913.86M, a 7.54% increase from fiscal 2023.
- Progyny, Inc. cost of goods and services sold for fiscal 2023 was $849.80M, a 37.16% increase from fiscal 2022.
- Progyny, Inc. cost of goods and services sold for fiscal 2022 was $619.59M, a 59.49% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $261.21M 10-Q · filed 2026-08-07 | $506.64M 10-Q · filed 2026-08-07 | $748.16M derived: sum of 3 quarters · filed 2026-08-07 | $988.68M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $245.43M 10-Q · filed 2026-05-08 | $486.95M derived: sum of 2 quarters · filed 2026-05-08 | $727.47M derived: sum of 3 quarters · filed 2026-05-08 | $981.37M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $241.52M 10-K · filed 2026-02-27 | $482.03M derived: sum of 2 quarters · filed 2026-02-27 | $735.93M derived: sum of 3 quarters · filed 2026-08-07 | $984.18M 10-K · filed 2026-02-27 |
| 2025-09-30 | $240.51M 10-K · filed 2026-02-27 | $494.41M derived: sum of 2 quarters · filed 2026-08-07 | $742.65M 10-Q · filed 2025-11-07 | $977.65M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $253.90M 10-Q · filed 2026-08-07 | $502.14M 10-Q · filed 2026-08-07 | $737.14M derived: sum of 3 quarters · filed 2026-08-07 | $964.52M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $248.24M 10-Q · filed 2026-05-08 | $483.24M derived: sum of 2 quarters · filed 2026-05-08 | $710.62M derived: sum of 3 quarters · filed 2026-05-08 | $946.43M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $235.00M 10-K · filed 2026-02-27 | $462.38M derived: sum of 2 quarters · filed 2026-02-27 | $698.19M derived: sum of 3 quarters · filed 2026-02-27 | $913.86M 10-K · filed 2026-02-27 |
| 2024-09-30 | $227.38M 10-K · filed 2026-02-27 | $463.19M derived: sum of 2 quarters · filed 2026-02-27 | $678.86M 10-Q · filed 2025-11-07 | $891.90M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $235.81M 10-K · filed 2026-02-27 | $451.48M 10-Q · filed 2025-08-08 | $664.52M derived: sum of 3 quarters · filed 2026-02-27 | $882.79M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $215.67M 10-K · filed 2026-02-27 | $428.72M derived: sum of 2 quarters · filed 2026-02-27 | $646.99M derived: sum of 3 quarters · filed 2026-02-27 | $865.72M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $213.05M 10-K · filed 2025-03-03 | $431.31M derived: sum of 2 quarters · filed 2025-03-03 | $650.04M derived: sum of 3 quarters · filed 2025-03-03 | $849.80M 10-K · filed 2026-02-27 |
| 2023-09-30 | $218.27M 10-K · filed 2025-03-03 | $437.00M derived: sum of 2 quarters · filed 2025-03-03 | $636.75M 10-Q · filed 2024-11-12 | $806.58M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $218.73M 10-K · filed 2025-03-03 | $418.49M 10-Q · filed 2024-08-07 | $588.31M derived: sum of 3 quarters · filed 2025-03-03 | $747.69M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $199.75M 10-K · filed 2025-03-03 | $369.58M derived: sum of 2 quarters · filed 2025-03-03 | $528.96M derived: sum of 3 quarters · filed 2025-03-03 | $680.07M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $169.83M 10-K · filed 2024-02-29 | $329.20M derived: sum of 2 quarters · filed 2024-02-29 | $480.32M derived: sum of 3 quarters · filed 2024-02-29 | $619.59M 10-K · filed 2025-03-03 |
| 2022-09-30 | $159.38M 10-K · filed 2024-02-29 | $310.49M derived: sum of 2 quarters · filed 2024-02-29 | $449.76M 10-Q · filed 2023-11-08 | $552.20M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $151.12M 10-K · filed 2024-02-29 | $290.38M 10-Q · filed 2023-08-04 | $392.82M derived: sum of 3 quarters · filed 2024-02-29 | $486.62M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $139.27M 10-K · filed 2024-02-29 | $241.71M derived: sum of 2 quarters · filed 2024-02-29 | $335.50M derived: sum of 3 quarters · filed 2024-02-29 | $434.53M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $102.44M 10-K · filed 2023-03-01 | $196.23M derived: sum of 2 quarters · filed 2023-03-01 | $295.26M derived: sum of 3 quarters · filed 2023-03-01 | $388.49M 10-K · filed 2024-02-29 |
| 2021-09-30 | $93.79M 10-K · filed 2023-03-01 | $192.82M derived: sum of 2 quarters · filed 2023-03-01 | $286.05M 10-Q · filed 2022-11-04 | $365.68M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $99.03M 10-K · filed 2023-03-01 | $192.26M 10-Q · filed 2022-08-05 | $271.89M derived: sum of 3 quarters · filed 2023-03-01 | $349.98M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $93.23M 10-K · filed 2023-03-01 | $172.86M derived: sum of 2 quarters · filed 2023-03-01 | $250.95M derived: sum of 3 quarters · filed 2023-03-01 | $303.60M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $79.64M 10-K · filed 2022-03-01 | $157.73M derived: sum of 2 quarters · filed 2022-03-01 | $210.38M derived: sum of 3 quarters · filed 2022-03-01 | $274.80M 10-K · filed 2023-03-01 |
| 2020-09-30 | $78.09M 10-K · filed 2022-03-01 | $130.74M derived: sum of 2 quarters · filed 2022-03-01 | $195.16M 10-Q · filed 2021-11-08 | $248.52M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $52.65M 10-K · filed 2022-03-01 | $117.07M 10-Q · filed 2021-08-06 | $170.43M derived: sum of 3 quarters · filed 2022-03-01 | $219.30M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $64.42M 10-K · filed 2022-03-01 | $117.78M derived: sum of 2 quarters · filed 2022-03-01 | $166.65M derived: sum of 3 quarters · filed 2022-03-01 | $211.37M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $53.35M 10-K · filed 2021-03-01 | $102.23M derived: sum of 2 quarters · filed 2021-03-01 | $146.94M derived: sum of 3 quarters · filed 2021-03-01 | $184.18M 10-K · filed 2022-03-01 |
| 2019-09-30 | $48.88M 10-K · filed 2021-03-01 | $93.59M derived: sum of 2 quarters · filed 2021-03-01 | $130.82M 10-Q · filed 2020-11-06 | $154.60M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $44.72M 10-K · filed 2021-03-01 | $81.95M 10-Q · filed 2020-08-07 | $105.72M derived: sum of 3 quarters · filed 2021-03-01 | $128.47M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $37.23M 10-K · filed 2021-03-01 | $61.01M derived: sum of 2 quarters · filed 2021-03-01 | $83.76M derived: sum of 3 quarters · filed 2021-03-01 | $104.88M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $23.77M 10-K · filed 2020-03-10 | $46.52M derived: sum of 2 quarters · filed 2020-03-10 | $67.64M derived: sum of 3 quarters · filed 2020-03-10 | $85.97M 10-K · filed 2021-03-01 |
| 2018-09-30 | $22.75M 10-K · filed 2020-03-10 | $43.87M derived: sum of 2 quarters · filed 2020-03-10 | $62.19M 10-Q · filed 2019-12-06 | |
| 2018-06-30 | $21.12M 10-K · filed 2020-03-10 | $39.44M derived: sum of 2 quarters · filed 2020-03-10 | ||
| 2018-03-31 | $18.32M 10-K · filed 2020-03-10 | |||
| 2017-12-31 | $41.18M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |